Literature DB >> 11865420

Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease.

Faris Bakri1, Aimee L Brauer, Sanjay Sethi, Timothy F Murphy.   

Abstract

To characterize the immune response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease (COPD), pre- and postexacerbation serum and sputum supernatant samples obtained during 21 exacerbations in 18 patients were studied, using the homologous infecting isolates. New serum immunoglobulin G (IgG) detected by whole-cell enzyme-linked immunosorbent assay developed after 12 (57.1%) of 21 exacerbations. Analysis of serum samples with flow cytometry, which detects antibodies that are exclusive to epitopes on the bacterial surface, revealed that 5 (23.8%) of the 21 exacerbations were associated with the development of new serum IgG to surface epitopes. Three of these serum samples and 2 other serum samples contained new IgG directed at lipooligosaccharide. Flow cytometry revealed that new mucosal IgA to surface-exposed epitopes of the infecting isolate developed in sputum supernatants after 42% of exacerbations. Therefore, adults with COPD develop variable humoral immune responses to M. catarrhalis after exacerbations, including new serum IgG and new mucosal IgA to epitopes on the bacterial surface.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865420     DOI: 10.1086/339174

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Multiplex PCR assay that identifies the major lipooligosaccharide serotype expressed by Moraxella catarrhalis clinical isolates.

Authors:  Katie J Edwards; Johanna M Schwingel; Anup K Datta; Anthony A Campagnari
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

2.  Discovery and Contribution of Nontypeable Haemophilus influenzae NTHI1441 to Human Respiratory Epithelial Cell Invasion.

Authors:  C P Ahearn; C Kirkham; L D Chaves; Y Kong; M M Pettigrew; T F Murphy
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

3.  Identification and characterization of a novel outer membrane protein (OMP J) of Moraxella catarrhalis that exists in two major forms.

Authors:  John P Hays; Saskia van Selm; Theo Hoogenboezem; Silvia Estevão; Kimberly Eadie; Peter van Veelen; Jan Tommassen; Alex van Belkum; Peter W M Hermans
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

4.  Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Christoph Aebi; Sanjay Sethi
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Characterization of a cluster of three glycosyltransferase enzymes essential for Moraxella catarrhalis lipooligosaccharide assembly.

Authors:  Katie J Edwards; Simon Allen; Bradford W Gibson; Anthony A Campagnari
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

6.  Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response.

Authors:  Timothy F Murphy; Aimee L Brauer; Brydon J B Grant; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2005-04-01       Impact factor: 21.405

Review 7.  A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 8.  Chronic obstructive pulmonary disease: role of bacteria and updated guide to antibacterial selection in the older patient.

Authors:  G Iyer Parameswaran; Timothy F Murphy
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 9.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.